PROGRESS IN NEURO-PSYCHOPHARMACOLOGY & BIOLOGICAL PSYCHIATRY

metrics 2024

Fostering Insights into Brain Function and Mental Health

Introduction

PROGRESS IN NEURO-PSYCHOPHARMACOLOGY & BIOLOGICAL PSYCHIATRY, published by PERGAMON-ELSEVIER SCIENCE LTD, is a leading peer-reviewed journal that serves the interdisciplinary field of neuropsychopharmacology and biological psychiatry. With an impressive impact factor in the first quartile of both Biological Psychiatry and Pharmacology categories, this journal provides a critical platform for the dissemination of cutting-edge research and innovative therapeutic approaches. Covering a broad range of topics from the molecular mechanisms underlying psychiatric disorders to advanced pharmacological interventions, it aims to foster scientific dialogue among researchers, clinicians, and students alike. The journal has been at the forefront of scientific inquiry since its inception in 1982 and continues to evolve, adapting to the ever-changing landscape of neuroscience and mental health research. With its focus on high-quality articles and a commitment to advancing the understanding of neuropsychopharmacology, this journal is essential for anyone interested in the complexities of brain function and mental health.

Metrics 2024

SCIMAGO Journal Rank1.65
Journal Impact Factor5.30
Journal Impact Factor (5 years)4.90
H-Index150
Journal IF Without Self5.30
Eigen Factor0.01
Normal Eigen Factor3.27
Influence1.41
Immediacy Index0.70
Cited Half Life6.90
Citing Half Life8.40
JCI1.43
Total Documents5214
WOS Total Citations14042
SCIMAGO Total Citations58169
SCIMAGO SELF Citations2187
Scopus Journal Rank1.65
Cites / Document (2 Years)6.14
Cites / Document (3 Years)5.63
Cites / Document (4 Years)5.58

Metrics History

Rank 2024

Scopus

Pharmacology in Pharmacology, Toxicology and Pharmaceutics
Rank #26/313
Percentile 91.69
Quartile Q1
Biological Psychiatry in Neuroscience
Rank #5/51
Percentile 90.20
Quartile Q1

IF (Web Of Science)

CLINICAL NEUROLOGY
Rank 30/277
Percentile 89.40
Quartile Q1
NEUROSCIENCES
Rank 44/310
Percentile 86.00
Quartile Q1
PHARMACOLOGY & PHARMACY
Rank 34/354
Percentile 90.50
Quartile Q1
PSYCHIATRY
Rank 28/276
Percentile 90.00
Quartile Q1

JCI (Web Of Science)

CLINICAL NEUROLOGY
Rank 32/278
Percentile 88.49
Quartile Q1
NEUROSCIENCES
Rank 38/310
Percentile 87.74
Quartile Q1
PHARMACOLOGY & PHARMACY
Rank 28/354
Percentile 92.09
Quartile Q1
PSYCHIATRY
Rank 32/276
Percentile 88.41
Quartile Q1

Quartile History

Similar Journals

Frontiers in Psychiatry

Advancing the Science of Mental Health
Publisher: FRONTIERS MEDIA SAISSN: 1664-0640Frequency: 1 issue/year

Frontiers in Psychiatry is a leading journal dedicated to advancing research within the field of psychiatry and mental health. Published by FRONTIERS MEDIA SA, the journal has established a commendable reputation since its inception, reflected in its Q1 status in the 2023 Psychiatry and Mental Health category and a robust ranking of 142 out of 567 in the Scopus database. With an open access model initiated in 2009, Frontiers in Psychiatry aims to disseminate high-quality research to a global audience, fostering collaboration and innovation among researchers, clinicians, and students alike. The journal covers a broad spectrum of topics, including neurobiology, psychosocial factors, treatments, and public health implications of mental disorders, ensuring comprehensive representation of contemporary psychiatric science. Located in Lausanne, Switzerland, and running until 2024, the journal not only emphasizes the importance of mental health research but also encourages interdisciplinary discourse, making it an essential resource for anyone invested in the well-being of individuals and communities alike.

INTERNATIONAL JOURNAL OF PSYCHIATRY IN CLINICAL PRACTICE

Pioneering insights in clinical psychiatry and mental health.
Publisher: TAYLOR & FRANCIS LTDISSN: 1365-1501Frequency: 4 issues/year

INTERNATIONAL JOURNAL OF PSYCHIATRY IN CLINICAL PRACTICE is a distinguished publication in the field of Psychiatry and Mental Health, published by TAYLOR & FRANCIS LTD in the United Kingdom. With an impressive 2023 impact factor that places it in the Q2 category among its peers, this journal is an essential resource for researchers, clinicians, and students dedicated to advancing mental health practices and understanding psychiatric disorders. Covering topics from clinical studies to innovative treatment methodologies, the journal welcomes original research, reviews, and case studies that contribute valuable insights into clinical practice. Accessible without any open access restrictions, the journal has been a pivotal platform since its inception in 1997, facilitating knowledge exchange in the field up to 2024. As evidenced by its notable Scopus ranking within the top 73rd percentile of Psychiatry and Mental Health, it remains committed to impacting clinical practices significantly.

Translational Psychiatry

Exploring the frontiers of psychiatric science.
Publisher: SPRINGERNATUREISSN: 2158-3188Frequency: 1 issue/year

Translational Psychiatry, an esteemed journal published by SpringerNature, is at the forefront of research in the fields of biological psychiatry, neuroscience, and mental health. With an impressive Q1 category ranking in Biological Psychiatry, Cellular and Molecular Neuroscience, and Psychiatry and Mental Health, the journal fosters high-quality scholarly work that informs clinical practices and guides future research directions. Since its inception in 2011, Translational Psychiatry has embraced the Open Access model, ensuring that groundbreaking findings are easily accessible to all, promoting collaboration and innovation within the global scientific community. With a solid ranking in Scopus—particularly at #33 out of 567 in Psychiatry and Mental Health and #6 out of 51 in Biological Psychiatry—this journal plays a critical role in advancing our understanding of mental health disorders, bridging the gap between bench science and clinical application. As it continues evolving through its converged years from 2011 to 2024, Translational Psychiatry remains an essential resource for researchers, healthcare professionals, and students dedicated to improving mental health outcomes.

INTERNATIONAL JOURNAL OF NEUROPSYCHOPHARMACOLOGY

Leading the charge in mental health research advancements.
Publisher: OXFORD UNIV PRESSISSN: 1461-1457Frequency: 12 issues/year

The INTERNATIONAL JOURNAL OF NEUROPSYCHOPHARMACOLOGY, published by OXFORD UNIV PRESS, is a leading open-access journal in the fields of pharmacology and psychiatry, with an impressive impact factor reflecting its prominence in academic research. Since its inception in 1998, the journal has provided a crucial platform for the publication of high-quality research, offering insights into the effects of neuropharmacological agents on mental health. As of 2023, it ranks in the Q1 category for both Pharmacology and Psychiatry & Mental Health, underscoring its relevance and authority within the scientific community. With notable rankings in various medical subspecialties, it attracts contributions that advance our understanding of psychiatric disorders and therapeutic strategies. The accessible nature of the journal, following its transition to open access in 2015, has expanded its reach, making knowledge and findings readily available to researchers, professionals, and students globally. This commitment to disseminating impactful research ensures the journal remains at the forefront of neuropsychopharmacological advancements.

PSYCHIATRIC GENETICS

Bridging Genetics and Psychiatry for Better Mental Health Solutions
Publisher: LIPPINCOTT WILLIAMS & WILKINSISSN: 0955-8829Frequency: 6 issues/year

PSYCHIATRIC GENETICS, published by LIPPINCOTT WILLIAMS & WILKINS, is a pivotal journal dedicated to the interdisciplinary study of genetic factors in psychiatric disorders, bridging the fields of genetics, psychiatry, and neuroscience. With a commitment to advancing research from its inception in 1990 and continuing through 2024, the journal provides a platform for innovative studies and findings that explore the genetic underpinnings of mental health. Although not currently an Open Access publication, it reaches a wide audience concerned with the complex interplay between genetics and psychiatric conditions, contributing to its Q3 and Q2 quartile rankings across multiple relevant categories in 2023. The importance of this journal cannot be understated; it serves as a crucial resource for researchers, clinicians, and students eager to uncover insights that could lead to more effective interventions and treatments in the realm of mental health.

Iranian Journal of Psychiatry and Behavioral Sciences

Pioneering Discussions in Behavioral Science and Psychiatry
Publisher: BRIEFLANDISSN: 1735-8639Frequency: 4 issues/year

Iranian Journal of Psychiatry and Behavioral Sciences, published by BRIEFLAND, is a pivotal platform for scholars and practitioners in the fields of psychiatry and behavioral sciences. With its ISSN 1735-8639 and E-ISSN 1735-9287, this journal primarily caters to the Iranian context while fostering a global dialogue on contemporary issues in mental health, behavioral neurology, and biological psychiatry. Since its inception in 2007, the journal has committed to disseminating high-quality research and reviews, thereby contributing to its categorization in the fourth quartile (Q4) for both Behavioral Neuroscience and Biological Psychiatry as of 2023. Although currently lacking an open access model, the journal's accessibility to critical research discussions is vital for enhancing knowledge among researchers, professionals, and students alike. With emerging relevance in the Iranian mental health landscape, it aims to bridge gaps in understanding and promote evidence-based practices from 2007 to 2024 and beyond.

BEHAVIOURAL PHARMACOLOGY

Advancing Insights in Behavioral Pharmacology
Publisher: LIPPINCOTT WILLIAMS & WILKINSISSN: 0955-8810Frequency: 8 issues/year

Behavioural Pharmacology is a distinguished academic journal published by Lippincott Williams & Wilkins, focusing on the intricate relationship between pharmacology, psychiatry, and behavioral science. With an ISSN of 0955-8810 and an E-ISSN of 1473-5849, this journal serves as a vital platform for researchers and professionals dedicated to exploring the pharmacological mechanisms underlying behavior and mental health. Operating with a robust track record since its inception in 1992, it has established itself in the academic community, as reflected by its Q3 rankings in both the pharmacology and psychiatry categories for 2023. Additionally, the journal holds a credible position in Scopus rankings, with a percentile ranking indicative of significant contributions to the fields of pharmacology and psychiatry. Aimed at advancing knowledge and disseminating research in the behavioral pharmacology domain, this journal is an essential resource for students, researchers, and clinical professionals seeking to stay at the forefront of this rapidly evolving field. While it is not an open access journal, the rich content and research findings published here continue to foster collaboration and innovation within the community, making it a crucial reference point for current and future studies.

JOURNAL OF BEHAVIOR THERAPY AND EXPERIMENTAL PSYCHIATRY

Pioneering insights in experimental psychiatry.
Publisher: PERGAMON-ELSEVIER SCIENCE LTDISSN: 0005-7916Frequency: 4 issues/year

Welcome to the Journal of Behavior Therapy and Experimental Psychiatry, a distinguished publication in the field of psychological research, recognized for its commitment to advancing knowledge in behavior therapy and experimental psychiatry. Published by Pergamon-Elsevier Science Ltd in the United Kingdom, this journal plays a crucial role in disseminating innovative findings and theoretical advancements since its inception in 1970. With an impressive array of impact factors, this journal proudly holds a Q1 ranking in Arts and Humanities (miscellaneous) and Q2 rankings across Clinical Psychology, Experimental and Cognitive Psychology, and Psychiatry and Mental Health categories in 2023. The journal provides a platform for both established researchers and emerging scholars to share insights that enhance practice and inform policy in mental health. Although not an Open Access journal, it ensures broad accessibility to its content through institutional subscriptions and affiliations. By focusing on high-quality, rigorous research, the Journal of Behavior Therapy and Experimental Psychiatry continues to shape the understanding of behavioral interventions and their psychological implications, making it an indispensable resource for professionals and students alike.

PSYCHIATRY RESEARCH

Shaping the future of psychiatry through impactful findings.
Publisher: ELSEVIER IRELAND LTDISSN: 0165-1781Frequency: 12 issues/year

PSYCHIATRY RESEARCH is a leading journal published by Elsevier Ireland Ltd, dedicated to advancing the field of psychiatry and mental health through the dissemination of rigorous research. With an impressive impact factor and categorized in the top quartile (Q1) of both Biological Psychiatry and Psychiatry and Mental Health in 2023, this journal ranks 14th in the field of Medicine _ Psychiatry and Mental Health out of 567 journals, and 4th in Neuroscience _ Biological Psychiatry out of 51, showcasing its influence and quality. Since its inception in 1979, PSYCHIATRY RESEARCH has provided a platform for innovative studies, clinical trials, and comprehensive reviews aimed at understanding the complexities of mental health disorders. Although it operates under a traditional access model, the journal remains committed to making vital research available to the academic community, ensuring that both seasoned professionals and budding researchers have access to groundbreaking findings. Positioned as a hub for psychiatric research, it caters to a diverse audience including clinicians, psychologists, and students, empowering them to contribute to the evolving landscape of mental health care.

ACTAS ESPANOLAS DE PSIQUIATRIA

Empowering the psychiatry community with open access insights.
Publisher: JUAN JOSE LOPEZ-IBOR FOUNDATIONISSN: 1139-9287Frequency: 6 issues/year

ACTAS ESPANOLAS DE PSIQUIATRIA, published by the renowned JUAN JOSE LOPEZ-IBOR FOUNDATION, serves as a vital resource in the field of psychiatry and mental health, particularly within the Spanish-speaking academic community. With its ISSN 1139-9287 and E-ISSN 1578-2735, this journal has been a critical platform for disseminating high-quality research since its inception in 1996 and continues to contribute valuable insights until 2024. As a recognized journal in the Q3 category of psychiatry and mental health, it ranks 387 out of 567 in Scopus, placing it within the 31st percentile, thereby indicating a growing influence among its peers. The journal’s open access options enhance its accessibility, encouraging a broader readership to engage with contemporary research issues in mental health. Researchers, professionals, and students alike will find ACTAS ESPANOLAS DE PSIQUIATRIA essential for staying informed on the latest developments and innovations in psychiatric practice and research.